Envista (NYSE:NVST) Price Target Lowered to $19.00 at Robert W. Baird

Envista (NYSE:NVST) had its price target decreased by Robert W. Baird from $22.00 to $19.00 in a report issued on Thursday, Benzinga reports. Robert W. Baird currently has a neutral rating on the stock.

NVST has been the subject of several other research reports. Morgan Stanley cut Envista from an overweight rating to an equal weight rating and lowered their price target for the company from $33.00 to $21.00 in a report on Friday, April 26th. Leerink Partnrs restated an underperform rating on shares of Envista in a report on Monday, February 26th. Jefferies Financial Group downgraded shares of Envista from a buy rating to a hold rating and cut their price target for the stock from $30.00 to $23.00 in a research note on Friday, February 9th. William Blair cut shares of Envista from an outperform rating to a market perform rating in a research note on Thursday, February 8th. Finally, TheStreet lowered Envista from a c rating to a d+ rating in a research report on Wednesday, February 7th. Three research analysts have rated the stock with a sell rating, seven have assigned a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat, Envista presently has a consensus rating of Hold and an average target price of $25.86.

Envista Stock Performance

Shares of NVST opened at $19.00 on Thursday. Envista has a 1 year low of $18.09 and a 1 year high of $36.74. The company’s 50 day simple moving average is $20.66 and its 200 day simple moving average is $22.50. The company has a debt-to-equity ratio of 0.34, a current ratio of 2.27 and a quick ratio of 1.93.

Envista (NYSE:NVST) last issued its quarterly earnings results on Wednesday, May 1st. The company reported $0.26 earnings per share for the quarter, missing analysts’ consensus estimates of $0.31 by ($0.05). The business had revenue of $623.60 million for the quarter, compared to analysts’ expectations of $634.85 million. Envista had a positive return on equity of 5.84% and a negative net margin of 4.70%. The company’s revenue for the quarter was down .6% compared to the same quarter last year. During the same period in the prior year, the company earned $0.38 EPS. As a group, research analysts forecast that Envista will post 1.26 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. raised its holdings in shares of Envista by 5.8% during the 4th quarter. Vanguard Group Inc. now owns 17,167,767 shares of the company’s stock valued at $413,056,000 after buying an additional 944,596 shares during the period. Ariel Investments LLC raised its stake in shares of Envista by 4.3% during the third quarter. Ariel Investments LLC now owns 5,335,578 shares of the company’s stock valued at $148,756,000 after purchasing an additional 218,461 shares during the period. Franklin Resources Inc. lifted its position in shares of Envista by 65.3% during the fourth quarter. Franklin Resources Inc. now owns 5,262,092 shares of the company’s stock worth $126,606,000 after purchasing an additional 2,077,786 shares in the last quarter. Nuance Investments LLC boosted its stake in shares of Envista by 953.8% in the fourth quarter. Nuance Investments LLC now owns 3,931,054 shares of the company’s stock valued at $94,581,000 after purchasing an additional 3,558,031 shares during the period. Finally, River Road Asset Management LLC acquired a new stake in Envista during the 4th quarter valued at $54,931,000.

About Envista

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.